Shareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-14 02:21:012019-01-17 02:33:14AVITA Medical Announces Results of Extraordinary General Meeting
Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-08 02:05:312019-01-17 02:20:18AVITA Medical Announces U.S. National Market Launch of RECELL® System
January 5, 2019 Excerpted from BioWorld MedTech, Volume 22, No.109, June 6, 2018 By David Godkin, Staff Writer The global orthopedic implants market valued at $47 billion in 2016 is expected to grow to $75 billion by 2023. To get a piece of that action, lead investors at Vancouver, B.C.-based Quark Venture Inc. are investing $10 million in Chirp data analytics […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-05 02:50:292019-01-08 02:52:01BioWorld Medtech – Canadian med tech, venture capital firm go global with medical implant analytics
Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by existing C3J shareholders upon closing The companies plan to hold a joint conference call on […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2019-01-04 03:05:462019-01-07 03:10:34AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
Valencia, Calif., USA, and Melbourne, Australia, 20 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-21 00:05:132018-12-21 00:05:13AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360
AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-18 23:01:532018-12-20 23:02:32AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
Valencia, Calif., USA, and Melbourne, Australia, 18 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-17 23:47:352018-12-20 23:57:42AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
Valencia, Calif., USA, and Melbourne, Australia, 16 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-16 23:12:012018-12-20 23:23:18AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
ARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-05 23:04:122018-12-20 23:10:21ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
Valencia, Calif., USA, and Melbourne, Australia, 4 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2018-12-04 23:24:092018-12-20 23:46:54AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement Share purchase plan (SPP) also announced to allow eligible shareholders to purchase up to A$3.0 million in shares
AVITA Medical Announces Results of Extraordinary General Meeting
/in Avita MedicalShareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]
AVITA Medical Announces U.S. National Market Launch of RECELL® System
/in Avita MedicalStrong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]
BioWorld Medtech – Canadian med tech, venture capital firm go global with medical implant analytics
/in CanaryJanuary 5, 2019 Excerpted from BioWorld MedTech, Volume 22, No.109, June 6, 2018 By David Godkin, Staff Writer The global orthopedic implants market valued at $47 billion in 2016 is expected to grow to $75 billion by 2023. To get a piece of that action, lead investors at Vancouver, B.C.-based Quark Venture Inc. are investing $10 million in Chirp data analytics […]
AmpliPhi Biosciences and C3J Therapeutics Agree to Merge
/in AmpliPhi BiosciencesTransaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by existing C3J shareholders upon closing The companies plan to hold a joint conference call on […]
AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 20 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA […]
AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development
/in AmpliPhi BiosciencesAmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]
AVITA Medical Announces Receipt of A$1.4 Million Research and Development Tax Credit
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 18 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office in the amount of A$1,421,000 for the year ending 30 June 2018. The R&D Tax […]
AVITA Medical Announces Hiring of Full U.S. Sales Team of Experienced Burn Professionals to Support National Launch of RECELL® System Strong market response to the RECELL System approval in advance of U.S. launch with 32 burn centers actively reviewing the product or placing commercial orders
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 16 November 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has completed hiring of the U.S. sales team to support the U.S. market launch of the RECELL® System for the treatment of acute thermal burns. The full direct sales team […]
ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
/in ArecorARECOR LIMITED (“Arecor” or “the Company”) ARECOR TO ATTEND THE 37TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE Cambridge, UK., 5 December 2018: Arecor Ltd (“the Company”), the UK-based specialty pharmaceutical company that develops superior biopharmaceuticals through the application of an innovative formulation technology platform, is pleased to announce today that its executive management team, Dr Sarah […]
AVITA Medical Announces Institutional Placement of A$40.0 Million to Support Commercialization and Pipeline Advancement Share purchase plan (SPP) also announced to allow eligible shareholders to purchase up to A$3.0 million in shares
/in Avita MedicalValencia, Calif., USA, and Melbourne, Australia, 4 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced an institutional placement of A$40.0 million (Institutional Placement) to fund the marketing and sales effort to support U.S. market launch of the RECELL® System, clinical and research and development to facilitate pipeline […]